Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Witkowska, Magdalena ^a   Smolewski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; APRIL PROTEIN; BORTEZOMIB; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; FORKHEAD TRANSCRIPTION FACTOR; LENALIDOMIDE; MITOXANTRONE; OXALIPLATIN; PREDNISONE; PROTEIN BCL 10; RITUXIMAB; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; VINCRISTINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANTIBIOTIC THERAPY; AUTOIMMUNE DISEASE; BACTERIAL VIRULENCE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHROMOSOME TRANSLOCATION; CHRONIC INFLAMMATION; CLINICAL FEATURE; ERADICATION THERAPY; FOLLOW UP; GASTRECTOMY; GENE MUTATION; HELICOBACTER INFECTION; HUMAN; MARGINAL ZONE LYMPHOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; STOMACH LYMPHOMA; STOMACH MARGINAL ZONE LYMPHOMA; STOMACH MUCOSA; IMMUNOLOGY; METABOLISM; PATHOLOGY; STOMACH TUMOR; COMPLICATION; LYMPHOMA, B-CELL, MARGINAL ZONE; STOMACH NEOPLASMS;

HELICOBACTER PYLORI;

HELICOBACTER INFECTIONS; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; NF-KAPPA B; STOMACH NEOPLASMS;

EID: 84876520642     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/523170     Document Type: Review

References (63)

1. Isaacson P., Du M., MALT lymphoma: from morphology to molecules. Nature Reviews 2004 52 4 644 653 (Pubitemid 39025059)
2. Swerdlow S. H., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2007 4th Lyon, France IARC
3. Weber D. M., Dimopoulos M. A., Anandu D. P., Pugh W. C., Steinbach G., Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology 1994 107 6 1835 1838 2-s2.0-0028053505 (Pubitemid 24357641)
4. Marshall B. J., Warren J. R., Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet 1984 1 8390 1311 1314 2-s2.0-0021259505 (Pubitemid 14111103)
5. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R. J., Helicobacter pylori infection and the development of gastric cancer. The New England Journal of Medicine 2001 345 11 784 789 2-s2.0-0035856021 10.1056/NEJMoa001999
6. Morgner A., Bayerdörffer E., Neubauer A., Stolte M., Malignant tumors of the stomach: gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori. Gastroenterology Clinics of North America 2000 29 3 593 607 2-s2.0-0033804182
7. Banks P. M., Gastrointestinal lymphoproliferative disorders. Histopathology 2007 50 1 42 54 2-s2.0-33845650674 10.1111/j.1365-2559.2006. 02571.x (Pubitemid 44953397)
8. O'Rourke J. L., Gene expression profiling in Helicobacter-induced MALT lymphoma with reference to antigen drive and protective immunization. Journal of Gastroenterology and Hepatology 2008 23 2 S151 S156 2-s2.0-57449104572 10.1111/j.1440-1746.2008.05553.x
9. Munari F., Lonardi S., Cassatella M. A., Doglioni C., Cangi M. G., Amedei A., Facchetti F., Eishi Y., Rugge M., Fassan M., De Bernard M., D'Elios M. M., Vermi W., Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood 2011 117 24 6612 6616 2-s2.0-79959196668 10.1182/blood-2010-06- 293266
10. Suarez F., Lortholary O., Hermine O., Lecuit M., Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006 107 8 3034 3044 2-s2.0-33645051417 10.1182/blood-2005-09-3679
11. Royer B., Cazals-Hatem D., Sibilia J., Agbalika F., Cayuela J. M., Soussi T., Maloisel F., Clauvel J. P., Brouet J. C., Mariette X., Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997 90 2 766 775 2-s2.0-0030872542 (Pubitemid 27299117)
12. Derringer G. A., Thompson L. D. R., Frommelt R. A., Bijwaard K. E., Heffess C. S., Abbondanzo S. L., Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. The American Journal of Surgical Pathology 2000 24 5 623 639 2-s2.0-0034099339 10.1097/00000478-200005000-00001 (Pubitemid 30253500)
13. Levine E. G., Arthur D. C., Machnicki J., Frizzera G., Hurd D., Peterson B., Gaji-Peczalska K. J., Bloomfield C. D., Four new recurring translocations in non-Hodgkin lymphoma. Blood 1989 74 5 1796 1800 2-s2.0-0024468639 (Pubitemid 19251562)
14. Starostik P., Patzner J., Greiner A., Schwarz S., Kalla J., Ott G., Müller-Hermelink H. K., Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 2002 99 1 3 9 2-s2.0-0036090299 10.1182/blood.V99.1.3 (Pubitemid 34532956)
15. Liu H., Ruskon-Fourmestraux A., Lavergne-Slove A., Ye H., Molina T., Bouhnik Y., Hamoudi R. A., Diss T. C., Dogan A., Megraud F., Rambaud J. C., Du M. Q., Isaacson P. G., Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. The Lancet 2001 357 9249 39 40 2-s2.0-0035814637 10.1016/S0140-6736(00)03571-6 (Pubitemid 32056501)
16. Streubel B., Simonitsch-Klupp I., Müllauer L., Lamprecht A., Huber D., Siebert R., Stolte M., Trautinger F., Lukas J., Püspök A., Formanek M., Assanasen T., Müller-Hermelink H. K., Cerroni L., Raderer M., Chott A., Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 2004 18 10 1722 1726 2-s2.0-6344223519 10.1038/sj.leu.2403501 (Pubitemid 39386353)
17. Ye H., Gong L., Liu H., Hamoudi R. A., Shirali S., Ho L., Chott A., Streubel B., Siebert R., Gesk S., Martin-Subero J. I., Radford J. A., Banerjee S., Nicholson A. G., Ranaldi R., Remstein E. D., Gao Z., Zheng J., Isaacson P. G., Dogan A., Du M. Q., MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. The Journal of Pathology 2005 205 3 293 301 2-s2.0-13844266269 10.1002/path.1715 (Pubitemid 40253919)
18. Remstein E. D., Dogan A., Einerson R. R., Paternoster S. F., Fink S. R., Law M., Dewald G. W., Kurtin P. J., The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. The American Journal of Surgical Pathology 2006 30 12 1546 1553 2-s2.0-33751419806 10.1097/01.pas.0000213275.60962.2a (Pubitemid 44815508)
19. Ruland J., Duncan G. S., Elia A., Del Barco Barrantes I., Nguyen L., Plyte S., Millar D. G., Bouchard D., Wakeham A., Ohashi P. S., Mak T. W., Bcl10 is a positive regulator of antigen receptor-induced activation of NF- B and neural tube closure. Cell 2001 104 1 33 42 2-s2.0-17744386318 10.1016/S0092-8674(01)00189-1 (Pubitemid 32144970)
20. Xue L., Morris S. W., Orihuela C., Tuomanen E., Cui X., Wen R., Wang D., Defective developmental and function of Bcl10-deficient follicular, marginal zone and B1 B cells. Nature Immunology 2003 4 9 857 865 2-s2.0-0041381357 10.1038/ni963 (Pubitemid 37098656)
21. Libra M., De Re V., Gloghini A., Gasparotto D., Gragnani L., Navolanic P. M., De Vita S., Mazzarino M. C., Zignego A. L., Carbone A., Boiocchi M., Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection. Haematologica 2004 89 7 873 874 2-s2.0-3242798980 (Pubitemid 38981354)
22. Streubel B., Vinatzer U., Lamprecht A., Raderer M., Chott A., T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005 19 4 652 658 2-s2.0-16844369469 10.1038/sj.leu.2403644 (Pubitemid 40521171)
23. Remstein E. D., Dogan A., Einerson R. R., Paternoster S. F., Fink S. R., Law M., Dewald G. W., Kurtin P. J., The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. The American Journal of Surgical Pathology 2006 30 12 1546 1553 2-s2.0-33751419806 10.1097/01.pas.0000213275.60962.2a (Pubitemid 44815508)
24. Haralambieva E., Adam P., Ventura R., Katzenberger T., Kalla J., Höller S., Hartmann M., Rosenwald A., Greiner A., Müller-Hermelink H. K., Banham A. H., Ott G., Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 2006 20 7 1300 1303 2-s2.0-33745194641 10.1038/sj.leu.2404244 (Pubitemid 43905839)
25. Sagaert X., De Paepe P., Libbrecht L., Vanhentenrijk V., Verhoef G., Thomas J., Wlodarska I., De Wolf-Peeters C., Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. Journal of Clinical Oncology 2006 24 16 2490 2497 2-s2.0-33744998398 10.1200/JCO.2006.05.6150 (Pubitemid 46630625)
26. Thome M., CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nature Reviews Immunology 2004 4 5 348 359 2-s2.0-2442612540 (Pubitemid 38649277)
27. Lin X., Wang D., The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling. Seminars in Immunology 2004 16 6 429 435 2-s2.0-8444225946 10.1016/j.smim.2004.08.022 (Pubitemid 39488023)
28. Pei Y. Y., Kuo S. H., Yeh K. H., Chuang S. E., Hsu C. H., Wen C. C., Lin H. I., Gao M., Cheng A. L., A pathway for tumor necrosis factor- α -induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF- B and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus. The Journal of Biological Chemistry 2006 281 1 167 175 2-s2.0-33644852482 10.1074/jbc.M511014200 (Pubitemid 43671175)
29. Batten M., Fletcher C., Ng L. G., Groom J., Wheway J., Laâbi Y., Xin X., Schneider P., Tschopp J., Mackay C. R., Mackay F., TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. Journal of Immunology 2004 172 2 812 822 2-s2.0-9144234090 (Pubitemid 38113737)
30. Novak A. J., Grote D. M., Stenson M., Ziesmer S. C., Witzig T. E., Habermann T. M., Harder B., Ristow K. M., Bram R. J., Jelinek D. F., Gross J. A., Ansell S. M., Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004 104 8 2247 2253 2-s2.0-4944262288 10.1182/blood-2004-02-0762 (Pubitemid 39331819)
31. Everhart J. E., Kruszon-Moran D., Perez-Perez G., Reliability of Helicobacter pylori and CagA serological assays. Clinical and Diagnostic Laboratory Immunology 2002 9 2 412 416 2-s2.0-0036127793 10.1128/CDLI.9.2.412- 416.2002 (Pubitemid 34226040)
32. Fox J. G., The non-H pylori helicobacters: their expanding role in gastrointestinal and systemic diseases. Gut 2002 50 2 273 283 2-s2.0-0036155986 10.1136/gut.0500273. (Pubitemid 34087945)
33. Zucca E., Dreyling M., Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010 21 supplement 5 v175 v176 2-s2.0-77954333591 10.1093/annonc/mdq182
34. Musshoff K., Schmidt Vollmer H., Prognosis of non Hodgkin's lymphomas with special emphasis on the staging classification. Zeitschrift fur Krebsforschung und Klinische Onkologie 1975 83 4 323 341 2-s2.0-0016846184
35. Zullo A., Hassan C., Cristofari F., Andriani A., De Francesco V., Ierardi E., Tomao S., Stolte M., Morini S., Vaira D., Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clinical Gastroenterology and Hepatology 2010 8 2 105 110 2-s2.0-75549090875 10.1016/j.cgh.2009.07.017
36. Caselli M., Zullo A., Maconi G., Parente F., Alvisi V., Casetti T., Sorrentino D., Gasbarrini G., 'Cervia II Working Group Report 2006': guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Digestive and Liver Disease 2007 39 8 782 789 2-s2.0-34447286014 10.1016/j.dld.2007.05.016 (Pubitemid 47046643)
37. Malfertheiner P., Megraud F., 'Morain C. O., Bazzoli F., El-Omar E., Graham D., Hunt R., Rokkas T., Vakil N., Kuipers E. J., Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 6 772 781 (Pubitemid 46854190)
38. Fock K. M., Katelaris P., Sugano K., Ang T. L., Hunt R., Talley N. J., Lam S. K., Xiao S. D., Tan H. J., Wu C. Y., Jung H. C., Hoang B. H., Kachintorn U., Goh K. L., Chiba T., Rani A. A., Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2009 24 10 1587 1600 2-s2.0-68749089263 10.1111/j.1440-1746.2009.05982.x
39. Zullo A., Hassan C., Andriani A., Cristofari F., De Francesco V., Ierardi E., Tomao S., Morini S., Vaira D., Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. The American Journal of Gastroenterology 2009 104 8 1932 1937 2-s2.0-68449095767 10.1038/ajg.2009.314
40. Koch P., Del Valle F., Berdel W. E., Willich N. A., Reers B., Hiddemann W., Grothaus-Pinke B., Reinartz G., Brockmann J., Temmesfeld A., Schmitz R., Rübe C., Probst A., Jaenke G., Bodenstein H., Junker A., Pott C., Schultze J., Heinecke A., Parwaresch R., Tiemann M., Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German multicenter study GIT NHL 01/92. Journal of Clinical Oncology 2001 19 18 3874 3883 2-s2.0-0035884660 (Pubitemid 32880066)
41. Bartlett D. L., Karpeh M. S. Jr., Filippa D. A., Brennan M. F., Long-term follow-up after curative surgery for early gastric lymphoma. Annals of Surgery 1996 223 1 53 62 2-s2.0-0030071215 10.1097/00000658-199601000-00008 (Pubitemid 26030032)
42. Yahalom J., MALT lymphomas: a radiation oncology viewpoint. Annals of Hematology 2001 80 supplement 3 B100 B105
43. Koch P., Probst A., Berdel W. E., Willich N. A., Reinartz G., Brockmann J., Liersch R., Del Valle F., Clasen H., Hirt C., Breitsprecher R., Schmits R., Freund M., Fietkau R., Ketterer P., Freitag E. M., Hinkelbein M., Heinecke A., Parwaresch R., Tiemann M., Treatment results in localized primary gastric lymphoma: data of patients registered within the German Multicenter study (GIT NHL 02/96). Journal of Clinical Oncology 2005 23 28 7050 7059 2-s2.0-27244444361 10.1200/JCO.2005.04.031
44. Yoon S. S., Coit D. G., Portlock C. S., Karpeh M. S., The diminishing role of surgery in the treatment of gastric lymphoma. Annals of Surgery 2004 240 1 28 37 2-s2.0-3042662423 10.1097/01.sla.0000129356.81281.0c (Pubitemid 38808231)
45. Nakamura S., Matsumoto T., Suekane H., Nakamura S., Matsumoto H., Esaki M., Yao T., Iida M., Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer 2005 104 3 532 540 2-s2.0-22544467450 10.1002/cncr.21152 (Pubitemid 41022810)
46. Zinzani P. L., Stefoni V., Musuraca G., Tani M., Alinari L., Gabriele A., Marchi E., Pileri S., Baccarani M., Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004 100 10 2190 2194 2-s2.0-2342570895 10.1002/cncr.20237 (Pubitemid 38580339)
47. Jäger G., Neumeister P., Brezinschek R., Hinterleitner T., Fiebiger W., Penz M., Neumann H. J., Mlineritsch B., DeSantis M., Quehenberger F., Chott A., Beham-Schmid C., Höfler G., Linkesch W., Raderer M., Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a Phase II study. Journal of Clinical Oncology 2002 20 18 3872 3877 2-s2.0-0037106369 10.1200/JCO.2002.05.117
48. Streubel B., Ye H., Du M. Q., Isaacson P. G., Chott A., Raderer M., Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 2004 66 6 476 480 2-s2.0-4644310793 10.1159/000079502 (Pubitemid 39370239)
49. Raderer M., Wohrer S., Bartsch R., Phase II Study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. Journal of Clinical Oncology 2005 23 33 8442 8446 10.1200/JCO.2004.00.8532
50. Jäger G., Neumeister P., Quehenberger F., Wöhrer S., Linkesch W., Raderer M., Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Annals of Oncology 2006 17 11 1722 1723 2-s2.0-33750579912 10.1093/annonc/mdl126 (Pubitemid 44680898)
51. Martinelli G., Laszlo D., Ferreri A. J. M., Pruneri G., Ponzoni M., Conconi A., Crosta C., Pedrinis E., Bertoni F., Calabrese L., Zucca E., Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti- Helicobacter pylori therapy. Journal of Clinical Oncology 2005 23 9 1979 1983 2-s2.0-20144368635 10.1200/JCO.2005.08.128 (Pubitemid 46211377)
52. Conconi A., Martinelli G., Lopez-Guillermo A., Zinzani P. L., Ferreri A. J. M., Rigacci L., Devizzi L., Vitolo U., Luminari S., Cavalli F., Zucca E., Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Annals of Oncology 2011 22 3 689 695 2-s2.0-79952025195 10.1093/annonc/mdq416
53. Raderer M., Wöhrer S., Streubel B., Drach J., Jäger U., Turetschek K., Troch M., Püspök A., Zielinski C. C., Chott A., Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006 70 6 411 417 2-s2.0-33847383821 10.1159/000098555 (Pubitemid 46335680)
54. Troch M., Kiesewetter B., Willenbacher W., Willenbacher E., Zebisch A., Linkesch W., Fridrik M., Müllauer L., Greil R., Raderer M., Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphomaof the mucosa associated lymphoid tissue-Lymphoma: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica 2013 98 2 264 268 10.3324/haematol.2012.072587
55. Kiesewetter B., Troch M., Dolak W., Müllauer L., Lukas J., Zielinski C. Ch., Raderer M., A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma). Haematologica. In press
56. McLaughlin P., Grillo-López A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 1998 16 8 2825 2833 2-s2.0-0345337254 (Pubitemid 28363048)
57. Conconi A., Martinelli G., Thiéblemont C., Ferreri A. J. M., Devizzi L., Peccatori F., Ponzoni M., Pedrinis E., Dell'Oro S., Pruneri G., Filipazzi V., Dietrich P. Y., Gianni A. M., Coiffier B., Cavalli F., Zucca E., Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003 102 8 2741 2745 2-s2.0-0141923917 10.1182/blood-2002-11- 3496 (Pubitemid 37248842)
58. Chaudhary N., Ozer H., Huard D., Lightfoot S., Mesiya S., Successful treatment of Helicobacter pylori -negative gastric MALT lymphoma with rituximab. Digestive Diseases and Sciences 2006 51 4 775 778 2-s2.0-33645842762 10.1007/s10620-006-3205-0
59. Salar A., Bellosillo B., Serrano S., Besses C., Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab. Journal of Clinical Oncology 2005 23 29 7361 7362 2-s2.0-33644667960 10.1200/JCO.2005.02.6138 (Pubitemid 46202349)
60. Zucca E., Conconi A., Martinelli G., Chlorambucil plus rituximab produces better eventfree survival in comparison with chlorambucil alone in the treatment of MALT lymphoma: 5-year analysis of the 2-arms part of the IELSG-19 randomized study. Blood 2010 116 432. (ASH Annual Meeting Abstracts)
61. Zullo A., Hassan C., Andriani A., Cristofari F., De Francesco V., Ierardi E., Tomao S., Morini S., Vaira D., Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. The American Journal of Gastroenterology 2009 104 8 1932 1937 2-s2.0-68449095767 10.1038/ajg.2009.314
62. Andriani A., Miedico A., Tedeschi L., Patti C., Di Raimondo F., Leone M., Schinocca L., Romanelli A., Bonanno G., Linea C., Giustini M., Hassan C., Cottone M., Zullo A., Management and long-term follow-up of early stage H. pylori -associated gastric MALT-lymphoma in clinical practice: an Italian, Multicentre study. Digestive and Liver Disease 2009 41 7 467 473 2-s2.0-66049088706 10.1016/j.dld.2008.09.009
63. Capelle L. G., de Vries A. C., Looman C. W. N., Casparie M. K., Boot H., Meijer G. A., Kuipers E. J., Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. European Journal of Cancer 2008 44 16 2470 2476 2-s2.0-54249154133 10.1016/j.ejca.2008.07.005